---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-002396"
form_type: "8-K"
ticker: "NXTC"
cik: "0001661059"
company_name: "NextCure, Inc."
filed_at: "2025-03-06T23:59:59+00:00"
generated_at: "2026-05-25T06:20:14.578161+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NextCure reports FY2024 net loss of $55.7M; cash $68.6M, LNCB74 Phase 1 advancing

## Summary
- Net loss of $55.7M in FY2024 improved from $62.7M in FY2023; R&D expenses $41.5M, G&A $15.7M, both down YoY.
- Cash, equivalents, and marketable securities $68.6M at Dec 31, 2024 (vs $108.3M); expected to fund operations into H2 2026.
- LNCB74 (B7-H4 ADC) Phase 1: completed cohort 1 in Feb 2025, currently dosing cohort 2; backfill cohorts planned H2 2025.
- Preclinical non-oncology programs (NC181 for Alzheimer's, NC605 for osteogenesis imperfecta) seeking partnerships.
- Potential IND filings for NC181 and NC605 within 12-18 months if partner or third-party funding secured.

## SEC filing metadata
- accession: 0001558370-25-002396
- form_type: 8-K
- ticker: NXTC
- cik: 0001661059
- company_name: NextCure, Inc.
- filed_at: 2025-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661059/000155837025002396/0001558370-25-002396-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661059/000155837025002396/nxtc-20250306x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-002396
- JSON: https://secwatch.observer/filing/0001558370-25-002396.json
- Plain text: https://secwatch.observer/filing/0001558370-25-002396.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.